Abbott Laboratories (ABT)
Cramer's Stop Trading: Abbott Labs
CNBC's Jim Cramer explains why he is keeping an eye on shares of Abbott Labs.
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Investors can find market-trouncing blue chip stocks in the healthcare industry.
Abbott (ABT) Outperforms Broader Market: What You Need to Know
Abbott (ABT) concluded the recent trading session at $113.64, signifying a +0.07% move from its prior day's close.
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott, Reckitt face trial over premature baby formula amid alarm from doctors
A Missouri mother and her lawyers this week will aim to convince a jury that Abbott , Reckitt's Mead Johnson and St. Louis Children's Hospital are responsible for a severe intestinal illness that she says her premature son got from the companies' formulas after he was born at the hospital.
2 Excellent Dividend Stocks to Buy With Less Than $200
Abbott Laboratories' top line was somewhat inconsistent in recent years due to swings in its COVID-related revenues. Johnson & Johnson has been restructuring, spinning off its consumer health segment and bolstering its medical device segment by acquiring Abiomed.
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
My Best Dividend Aristocrats For October 2024
The ProShares S&P 500 Dividend Aristocrats ETF extends it's good form in the second half of 2024, adding a gain of 3.69% in August. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 38 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher starting dividend yield.
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know
Abbott (ABT) closed the most recent trading day at $112.73, moving +0.11% from the previous trading session.
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
A market sell-off this summer resulted in an 8% loss for the S&P 500 over three weeks. These periods can happen at any time during a bull or bear market -- so it's important to prepare for them.
Here's Why Abbott (ABT) Fell More Than Broader Market
Abbott (ABT) closed the most recent trading day at $113.70, moving -0.39% from the previous trading session.
